Anti-tumor platinum-based drug mineralized protein nanoparticle, preparation method therefor and use thereof

Patent metadata

Field	Value
Publication number	US-12364667-B2
Application number	US-202117560155-A
Country	US
Kind code	B2
Filing date	Dec 22, 2021
Priority date	Aug 26, 2019
Publication date	Jul 22, 2025
Grant date	Jul 22, 2025

Abstract

Anti-tumor platinum drug mineralized protein nanoparticles and a preparation method therefor are disclosed. The anti-tumor platinum-based drug mineralized protein nanoparticles include a platinum drug and a protein. The protein is one or more selected from the group consisting of albumin, transferrin, hemoglobin, and low-density lipoprotein. The platinum drug is cisplatin, iodoplatin, bromoplatin, oxaliplatin, carboplatin, or nedaplatin. A drug loading of the anti-tumor platinum-based drug mineralized protein nanoparticles is 1% to 50%.

First claim

The invention claimed is:

1. Anti-tumor platinum drug mineralized protein nanoparticles, wherein the anti-tumor platinum drug mineralized protein nanoparticles comprise a platinum drug and a protein,
wherein the protein is selected from the group consisting of albumin, transferrin, hemoglobin, and lipoprotein; and the platinum drug is selected from the group consisting of cisplatin, iodoplatinum, bromoplatinum, oxaliplatin, carboplatin, and nedaplatin; and
wherein the platinum drug is contained in inner cavity of the protein, and wherein a mass ratio of the platinum drug-to-(the platinum drug and the protein) is in the range of 1%-50%.

2. A method for preparing anti-tumor platinum drug mineralized protein nanoparticles, wherein the method comprises the following steps:
(1) reacting a platinum drug and a silver salt in water and removing a precipitate to obtain a platinum prodrug compound aqueous solution; then mixing the platinum prodrug compound aqueous solution and a protein aqueous solution to obtain a platinum prodrug compound and protein complex mixture, the protein aqueous solution comprising a protein;
(2) adjusting a pH value of the platinum prodrug compound and protein complex mixture to 4-12, adding a ligand aqueous solution, purifying and lyophilizing to obtain the platinum drug mineralized protein nanoparticles,
wherein the protein is selected from the group consisting of albumin, transferrin, hemoglobin, and lipoprotein; and the platinum drug is selected from the group consisting of cisplatin, iodoplatinum, bromoplatinum, oxaliplatin, carboplatin, and nedaplatin; and
wherein the platinum drug is contained in a cavity of the protein to achieve controllable growth of a particle size of the platinum drug and to obtain a mineralization of the platinum drug.

3. The method for preparing anti-tumor platinum drug mineralized protein nanoparticles according to claim 2 , wherein, in step (1), a centrifugal separation is used to remove the precipitate, and the reaction between the platinum drug and the silver salt is conducted at 50-60° C. in absence of light for 3 hours, and then at room temperature for 10-12 hours; and in step (2), purifying is a centrifugal treatment in an ultrafiltration tube.

4. The method for preparing anti-tumor platinum drug mineralized protein nanoparticles according to claim 2 , wherein a molar ratio of the platinum drug to the silver salt is from 1:1 to 5:1; a molar ratio of the platinum prodrug compound to the protein is from 20:1 to 200:1; a molar ratio of the platinum prodrug compound to the ligand is from 1:1 to 1:16; and a concentration of the protein in the protein aqueous solution is 1-25 mg/mL.

5. The method for preparing anti-tumor platinum drug mineralized protein nanoparticles according to claim 4 , wherein the molar ratio of the platinum drug to the silver salt is from 2:1 to 4:1; the molar ratio of the platinum prodrug compound to the protein is from 50:1 to 150:1; the molar ratio of the platinum prodrug compound to the ligand is from 1:4 to 1:12; and the concentration of the protein in the protein aqueous solution is 3-20 mg/mL.

6. The method for preparing anti-tumor platinum drug mineralized protein nanoparticles according to claim 2 , wherein the ligand is selected from the group consisting of potassium chloride, potassium bromide, potassium iodide, 1,1-cyclobutane dicarboxylate, glycolate, oxalate, carbonate, and bicarbonate; and wherein the silver salt is silver nitrate or silver sulfate.

7. An anti-tumor platinum drug mineralized protein nanoparticles freeze-dried powder, wherein a method of preparing the anti-tumor platinum drug mineralized protein nanoparticles freeze-dried powder comprises the following steps:
(1) reacting a platinum drug and a silver salt in water and removing a precipitate to obtain a platinum prodrug compound aqueous solution; then mixing the platinum prodrug compound aqueous solution and an aqueous protein solution to obtain a platinum prodrug compound and protein complex mixture, the protein aqueous solution comprising a protein;
(2) adjusting a pH value of the platinum prodrug compound and protein complex mixture to 4-12, adding an aqueous ligand solution, purifying, and lyophilizing to obtain the anti-tumor platinum drug mineralized protein nanoparticles freeze-dried powder,
wherein the protein is selected from the group consisting of albumin, transferrin, hemoglobin, and lipoprotein; and the platinum drug is selected from the group consisting of cisplatin, iodoplatinum, bromoplatinum, oxaliplatin, carboplatin, and nedaplatin; and
wherein the platinum drug is contained in a cavity of the protein to achieve controllable growth of a particle size of the platinum drug and to obtain a mineralization of the platinum drug.

Assignees

• Univ Soochow

Inventors

• Chen Huabing
• Deng Yibin
• Yang Hong
• Ke Hengte
• Liu Ling
• Li Ting
• Yang Tao
• Wang Lu

Classifications

• A61K31/282

  Platinum compounds · CPC title

• A61K9/5192

  Processes · CPC title

• A61K33/243 Primary

  Platinum; Compounds thereof · CPC title

• A61K9/5169 Primary

  Proteins, e.g. albumin, gelatin · CPC title

• A61P35/00

  Antineoplastic agents · CPC title